Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about determining the Norwood level of hair loss. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A 32-year-old male with Norwood 3 and heavy diffuse thinning is starting a hair loss treatment including RU58841, Minoxidil, finasteride, derma rolling, vitamins, and possibly MK677, while cutting out most sugars from his diet. He plans to share progress photos and updates on his test levels.

A 23-year-old man shared his 4-month hair regrowth progress using 1mg oral finasteride daily, 5% minoxidil with finasteride topical twice a day, multivitamins, microneedling, head massages, and ketoconazole shampoo. He's unsure of his current Norwood scale classification and is asking for help to determine it, with suggestions ranging from NW4 to NW4.5.

Norwood 1-3 hair loss is considered normal in Russia and not balding. Using finasteride for Norwood 1-3 is seen as unnecessary and risky.

A 30-year-old with Norwood 3V hair loss uses finasteride 1.25 mg every other day and Minoxidil (Regaine 5%) twice daily, experiencing no side effects with the current regimen. The front hairline remains unchanged, but the crown appears better in certain lighting.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Ibrox1972 shared an 8.5-month update on their 2,689-graft hair transplant by Dr. Raghu Reddy in London, along with using oral finasteride, oral minoxidil, and microneedling. Users praised the natural-looking results and discussed the importance of choosing a skilled doctor.

User experienced hair loss from Norwood 3.5 to Norwood 5 with diffuse thinning after using a hair system for 2 years. Tried Redensyl, Capixyl, Bicapil, Biotin, multivitamins, Fin, and Min without significant improvement, seeking advice for hair recovery.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user improved their hair loss from stage 5 to stage 3 using Minoxidil, Finasteride, and a Dermapen. They saw results after 6 months, experienced a shedding phase, then saw more gains, advising others not to be discouraged during the shedding phase.

A 31-year-old male considering returning to finasteride at a lower dose or using topical finasteride to assess his Norwood scale for a potential future hair transplant. He previously stopped finasteride due to side effects and has been shaving his head.

A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

The user is hesitant to start a hair loss treatment regimen with Finasteride, Minoxidil, a derma stamp, and Nizoral shampoo due to concerns about potential side effects, despite being motivated by success stories. They seek advice from others who have faced similar dilemmas or have started treatment despite initial fears.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

A 41-year-old doctor shared his positive experience with a 4,100 graft hair transplant, highlighting the importance of a skilled doctor for a natural hairline. He mentioned a confidence boost and the occasional use of finasteride post-transplant.

The user began experiencing hair loss a few years ago at age 22 and is a diffuse thinner with a Norwood scale rating of 2. They have a naturally athletic build and gain muscle easily, with a hairy chest and stomach.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

The user is 2 months post-hair transplant with 6,000 grafts using the DHI method and is using oral finasteride, minoxidil, and vitamins. They are seeking feedback on their progress.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.